Trial Profile
Effect of LY3202626 on Alzheimer's Disease Progression as Measured by Cerebral ¹⁸F-AV-1451 Tau-PET in Mild Alzheimer's Disease Dementia
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs LY 3202626 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms NAVIGATE-AD
- Sponsors Eli Lilly and Company
- 20 Jul 2023 Results comparing BIN1 risk allele rs6733839 with APOE4 on interdependency among AD risk factors and biomarkers by applying Bayesian Network (BN) modeling to data from Lilly AD clinical trials (A05C (n=142, NCT01565382), A05E (n=217, NCT02016560), AZES (n=206, NCT02245737), LLCF (n=229, NCT02791191), and LZAX (n=194, NCT01900665) ), presented at the Alzheimer's Association International Conference 2023.
- 20 Jul 2023 Results of pooled analysis from NCT01900665, NCT02791191, NCT02245737, NCT02016560 assessing to understand the direct and indirect effects, mediated through amyloid levels, of the rs6733839 T-allele and APOE e4-allele on tau presented at the Alzheimer's Association International Conference 2023
- 04 Aug 2022 Results (n=431) is to apply data-driven methods on regional tau measurements at baseline to identify a relatively homogeneous patient population showing earlier signals of tau from NCT02016560, NCT01900665, NCT02791191 and NCT02245737 studies, presented at the Alzheimer's Association International Conference 2022.